Amicus Therapeutics Completes Merger with BioMarin, Becomes Wholly-Owned Subsidiary
Summary
Amicus Therapeutics, Inc. has completed its merger with BioMarin Pharmaceutical Inc.'s subsidiary, Lynx Merger Sub 1, Inc., resulting in Amicus becoming a wholly-owned subsidiary and terminating all public offerings.
Key Events
-
Merger Completion Confirmed
Amicus Therapeutics, Inc. has officially completed its merger with Lynx Merger Sub 1, Inc., a wholly-owned subsidiary of BioMarin Pharmaceutical Inc., making Amicus a wholly-owned subsidiary.
-
Public Offerings Terminated
All offerings and sales of securities under various S-3 Registration Statements have been terminated following the merger completion.
-
Securities Deregistered
Amicus is removing all registered but unsold securities from registration with the SEC, signifying the end of its public trading status.
Analysis
This filing confirms the definitive completion of the merger between Amicus Therapeutics and Lynx Merger Sub 1, Inc., a subsidiary of BioMarin Pharmaceutical Inc. This major corporate event transforms Amicus into a private entity, marking the end of its life as an independent publicly traded company. As a direct consequence, Amicus has initiated the deregistration of all previously registered but unsold securities. This follows the final French regulatory clearance announced on April 23, 2026, and finalizes the acquisition process. For existing shareholders, this event typically signifies the realization of the merger consideration.
At the time of this filing, FOLD was trading at $14.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.5B. The 52-week trading range was $5.51 to $14.50. This filing was assessed with neutral market sentiment and an importance score of 10 out of 10.